Omios Biologics

Executive Summary

Omios Biologics is a private biotechnology company developing next-generation oncolytic virus (OV) immunotherapies for solid tumors. Its proprietary platform leverages a novel modified vaccinia virus designed to selectively replicate in and destroy cancer cells while stimulating a systemic anti-tumor immune response. The company is initially targeting major indications including breast, liver, and colon cancers. Founded in 2018 and headquartered in San Diego, Omios is positioned in the competitive OV space, but its differentiated approach may offer advantages in tumor selectivity and immune activation. The company has not disclosed funding rounds or valuation, suggesting it may still be in early preclinical or IND-enabling stages. Success will depend on advancing its lead program into the clinic and securing partnerships or further investment to fund development.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Oncolytic Virus Candidate40% success
• Q2 2026Preclinical Data Presentation at Major Oncology Conference60% success
• Q3 2026Strategic Partnership or Licensing Deal35% success